0001636050-19-000085.txt : 20190924
0001636050-19-000085.hdr.sgml : 20190924
20190924171515
ACCESSION NUMBER: 0001636050-19-000085
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190921
FILED AS OF DATE: 20190924
DATE AS OF CHANGE: 20190924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nassif David W.
CENTRAL INDEX KEY: 0001636975
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 191111495
MAIL ADDRESS:
STREET 1: C/O STEADYMED THERAPEUTICS, INC.
STREET 2: 2410 CAMINO RAMON
CITY: SAN RAMON
STATE: CA
ZIP: 94583
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
wf-form4_156935969903570.xml
FORM 4
X0306
4
2019-09-21
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001636975
Nassif David W.
C/O AXOVANT GENE THERAPIES LTD.,
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
0
1
0
0
Principal Financial Officer
Restricted Stock Units
2019-09-21
4
A
0
30120
0
A
Common Shares
30120.0
30120
D
Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.
/s/ David W. Nassif
2019-09-24